News · FDA and regulation

FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week

Briefing documents posted in June recommended against adding any of the seven to the 503A compounding list. The committee met on 23 and 24 July.

Event date 2026-07-23 · Published 2026-07-24 · EV-0810

What is being decided

The FDA Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider BPC-157, TB-500 and five other peptides for the 503A bulk drug substances list — the register of substances state-licensed pharmacies may lawfully compound from.

Briefing documents posted on 30 June recommended against adding them. The committee voted the other way. On 23 July 2026 it recommended BPC-157, KPV and TB-500 for inclusion by 8–6 with one abstention, and MOTS-c by 7–5 with two abstentions, overriding its own agency's staff reviewers. The votes are non-binding and the FDA decides through formal rulemaking, commonly 8 to 12 months. See our full report on the vote.

Why this sits alongside the GLP-1 decision

The two proceedings run in parallel and point the same way. The 503B bulks proposal would close outsourcing-facility compounding of semaglutide, tirzepatide and liraglutide. This one concerns whether a further set of peptides can be compounded at all under 503A.

Read together, they describe an agency tightening what may lawfully be compounded from bulk peptide substances, in a market where peptide compounding expanded rapidly during the shortage years.

What BPC-157 and TB-500 actually are

Both are peptides marketed widely in wellness and performance contexts for tissue repair and recovery. Neither is an approved drug. Neither has completed the trial programme an approval would require.

They circulate heavily in the same grey market that sells retatrutide and other investigational compounds — frequently labelled for research use, which is a complete answer about their regulatory status.

A negative determination would mean they cannot lawfully be compounded even by a state-licensed pharmacy, which removes the last route by which they could reach a patient through a prescriber.

Why patients on GLP-1s should care

Because these products are frequently sold alongside them. Providers offering compounded GLP-1s often list peptides in the same catalogue, and patients moving between them may not register that the regulatory status differs.

It also matters for how you read a provider. A company selling both a lawfully compounded GLP-1 and an unapproved research peptide is operating on both sides of a line, and that is information about its compliance posture.

What to establish about anything you are offered

1. Is this substance approved, lawfully compoundable, or neither?
2. Is there a named prescriber with a current state licence?
3. Is there a named pharmacy with a current licence?
4. Does any labelling say research use only?

The fourth question resolves most cases on its own.

Status

We are recording the committee meeting and the briefing document recommendation as reported, from secondary sources, pending capture of the agency's own materials and any subsequent determination. No final decision had published as of 24 July 2026.

If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.

Questions readers actually ask

Capture standing: 35 of 86 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.